Report Store | Pharma intelligence
  • My Account
    • 0Shopping Cart
  • $0.00
  • Disease analysis
    • Anemias
    • Bacterial infections
    • Bleeding disorders
    • Brain Cancer
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Cerebrovascular diseases
    • Dermatology
    • Diabetes and diabetic complications
    • Gastroenterology
    • Gastrointestinal cancer
    • Head and Neck Cancer
    • Hypertension
    • Immunology and Inflammation
    • Infectious Diseases
    • Ischemic heart disease
    • Leukemia
    • Lung Cancer
    • Lymphoma
    • Oncology overview
    • Market Spotlight
    • Mens Health
    • Neurology
    • Oncology
    • Ophthalmology
    • Other Hematological Cancers
    • Other metabolic diseases
    • Other Solid Cancers
    • Pain
    • Psychiatry
    • Respiratory
    • Rheumatology
    • Skin cancer
    • Thrombosis
    • Urological cancer
    • Vaccines
    • Viral infections
    • Women’s Health
  • Strategy analysis
    • Bleeding disorders
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Commercial Strategy
    • Dealmaking and R&D
    • Head and Neck Cancer
    • Hot Topics
    • Infectious Diseases
    • KOL Insight
    • Leukemia
    • Lung Cancer
    • Manufacturing
    • Market Access
    • Neurology
    • Oncology
    • Outsourcing
    • Pricing & Reimbursement
    • R&D
    • Regulatory & Therapeutic Area
    • Trends
    • Urological cancer
  • Company analysis
    • Big Pharma
    • Emerging Pharma
    • Hot Topics
    • Japan Pharma
    • M&A Analysis
    • Mid Pharma
  • Drug analysis
    • A
    • B-C
    • D-F
    • G-L
    • M-O
    • P-R
    • S-T
    • U-Z
  • MedTech analysis
    • Allergy
    • Autoimmune / Immunology
    • Cardiovascular
    • Dermatology
    • Endocrine
    • ENT / Dental
    • Gastroenterology
    • Hearing
    • Hematology
    • Infectious Diseases
    • Metabolic
    • Neurology
    • Obstetrics / Gynecology
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Osteoporosis
    • Psychiatry
    • Renal
    • Respiratory
    • Rheumatology
    • Urology
  • Opinion & analysis
    • Business Development
    • Business Management
    • Clinical Trials
    • Digital Health
    • Cybersecurity
    • Compliance & Risk
    • Digital patient management
    • Digital policy & regulation
    • Finance & Pricing
    • Healthcare Innovation
    • ICT and Health
    • Leadership
    • Legislation Regulation & Policy
    • Market Access
    • Market Intelligence
    • Medical
    • Pharmaceutical Device
    • Pharmaceutical Research
    • Strategy & Innovation
    • Tech companies & Data
    • Tech & Pharma
  • Blogs
  • Search
  • Menu
You are here: Home > Drug analysis

Drug analysis


  • Sort by Default
    • Default
    • Custom
    • Name
    • Price
    • Date
    • Popularity (sales)
    • Average rating
    • Relevance
    • Random
    • Product ID
  • Display 15 Products per page
    • 15 Products per page
    • 30 Products per page
    • 45 Products per page
  • Abraxane

    Read More

    Abraxane (nab-paclitaxel; Bristol-Myers Squibb) is a novel albumin-bound formulation of paclitaxel. Paclitaxel is an insoluble taxane classified as an anti-microtubule agent; it stops the growth of tumors by inhibiting mitosis during metaphase.

    February 26, 2020
    Find out more
  • bempedoic acid franchise

    Bempedoic Acid Franchise

    Read More

    Bempedoic acid is an orally administered small molecule that inhibits fatty acid and cholesterol synthesis.

    November 20, 2019
    Find out more
  • Repatha

    Repatha

    Read More

    Repatha (evolocumab; Amgen/Astellas) is a fully human monoclonal immunoglobulin G2 antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9).

    November 20, 2019
    Find out more
  • Vascepa

    Read More

    Vascepa (icosapent ethyl) is marketed by Amarin for the treatment of severe hypertriglyceridemia. The molecule itself is a semi-synthetic, highly purified derivative of the omega-3 fatty acid eicosapentaenoic acid (EPA).

    November 20, 2019
    Find out more
  • juxtapid report

    Juxtapid

    Read More

    Juxtapid (lomitapide mesylate) is a novel, first-in-class microsomal triglyceride transfer protein (MTP) inhibitor marketed by Aegerion.

    November 20, 2019
    Find out more
  • praluent report

    Praluent

    Read More

    Praluent (alirocumab; Sanofi/Regeneron) is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PSCK9) and is intended for the treatment of hypercholesterolemia.

    November 20, 2019
    Find out more
  • Waylivra

    Read More

    Waylivra (volanesorsen; Ionis Pharmaceuticals) is an antisense drug that inhibits the translation and production of ApoC-III.

    November 20, 2019
    Find out more
  • Inclisiran

    Read More

    Inclisiran (The Medicines Company/Alnylam Pharmaceuticals) is a systemically delivered siRNA therapeutic targeting mRNA for PCSK.

    November 20, 2019
    Find out more
  • Tymlos transdermal patch

    Read More

    Tymlos (abaloparatide; Radius Health) is a synthetic peptide analog of human parathyroid hormone-related protein (PTHrP), which binds to the same receptor as parathyroid hormone (PTH).

    October 8, 2019
    Find out more
  • Cabometyx

    Read More

    Cabometyx (cabozantinib; Exelixis/Ipsen/Takeda) is an orally available small molecule inhibitor which has been shown to suppress tumor growth and metastasis by inhibiting the activity of multiple tyrosine kinases including MET, AXL, and vascular endothelial growth factor receptor (VEGFR).

    September 9, 2019
    Find out more
  • Imfinzi

    Read More

    Imfinzi (durvalumab; AstraZeneca)  is a human monoclonal antibody directed against programmed death-ligand 1 (PD-L1).

    September 9, 2019
    Find out more
  • Lenvima

    Read More

    Lenvima (lenvatinib; Eisai/Novartis/Merck & Co) is an orally available small molecule inhibitor of multiple tyrosine kinases including vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR).

    September 9, 2019
    Find out more
  • tislelizumab

    Read More

    Tislelizumab (BeiGene) is a humanized monoclonal antibody that was designed to bind to the PD-1 receptor and prevent binding of PD-L1. In addition, tislelizumab was designed to minimize binding to Fc-gamma-receptors (FcyR) on macrophages.

    September 9, 2019
    Find out more
  • opdivo report

    Opdivo

    Read More

    Opdivo is a fully human immunoglobulin G4 PD-1 immune checkpoint inhibitor that binds to the checkpoint receptor PD-1 expressed on activated T cells.

    September 9, 2019
    Find out more
  • cyramza thumbnail

    Cyramza

    Read More

    Cyramza (ramucirumab; Eli Lilly/Shire) is a fully human vascular endothelial growth factor receptor (VEGFR)-2-directed immunoglobulin G1 monoclonal antibody that binds to the extracellular domain of VEGFR-2 found on tumor vasculature.

    September 9, 2019
    Find out more
Page 2 of 41
Page 2 of 41‹1234›»
  • Home
  • Terms and Conditions
  • Refund policy
  • Privacy Policy
  • Cookie Policy
  • Contact Us
  • About Us
  • Discounts
  • Market Spotlight – Reports
  • twitter
  • linkedin
  • Sitemap
Copyright © 2022 Pharma Intelligence UK Limited Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London, SW1P 1WG. Pharma Intelligence UK Limited is part of the Pharma Intelligence Group.

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Call Back
Scroll to top